Southern States Chapter of AACE 2018 Annual Meeting, New Orleans, LA., February 16-18, 2018

New Orleans, LA US
February 16, 2018 to February 18, 2018

Welcome, and thank you for attending the Southern States-AACE 2018 Annual Meeting.

The Southern States Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high-quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Endocrinologists, MD/DOs, advance practice clinicians, and other interested healthcare professionals who are interested in the treatment of endocrine disease states that reside or practice in the state of Alabama, Louisiana, Mississippi & Tennessee.

Learning Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices
  2. Describe the new 8th edition AJCC staging system
  3. Describe a rational approach to selection of thyroid cancer patients for lobectomy
  4. Describe a rational approach to active surveillance in low risk thyroid cancer
  5. Review the most recent information regarding the diagnosis and source localization of Cushing’s syndrome/disease
  6. Review the current state of the art in surgical and radio therapeutic options for Cushing’s disease
  7. Apply this knowledge in real-world, case-based diagnostic and treatment scenarios
  8. Describe, according to AACE Guidelines, steps for assessment and staging to direct medical management of obesity
  9. Discuss the safety and efficacy of currently available medications approved for chronic weight management
  10. Describe the efficacy and safety of common bariatric surgery procedures and the long term nutritional support of patients who have these procedures
  11. Understand the mechanism of action of denosumab
  12. Appreciate what happens to BMD, BTM and fracture risk when denosumab is stopped
  13. Understand new agents in development
  14. Analyze aldosterone/renin ratios in the context of medication and serum potassium
  15. Interpret the results of adrenal vein sampling
  16. List the medications that interfere with the evaluation of pheochromocytoma
  17. Review the importance of lipids in preventive cardiology
  18. Review the effects of statins but also limitations
  19. Describe what PCSK9's are
  20. Review correct billing and coding guidelines relating to endocrinology services
  21. Define areas of opportunities to improve documentation
  22. Describe resources that can be utilized to ensure appropriate coding and billing relating to endocrinology
  23. Describe symptoms and signs commonly presented by the pseudo-endocrine patient
  24. Review diagnostic evaluations appropriate for the pseudo-endocrine patient
  25. Discuss management strategies for the pseudo-endocrine patient
  26. Describe the causes of the high incidence of heart failure in the diabetes population
  27. Identify the oral hypoglycemic agents that increase and decrease the incidence of heart failure on the diabetes patient
  28. Recognize the need to screen for heart failure in the diabetes patient
  29. Identify ideologies for increased incidence of cardiovascular disease in the type diabetes patient
  30. Recognize the role of postprandial hyperglycemia and hypoglycemia
  31. Recognize results of GLP-1 receptor agonists in cardiovascular outcomes trails
  32. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 11.75 AMA
  • 11.75 Attendance
Course opens: 
02/16/2018
Course expires: 
02/17/2019
Event starts: 
02/16/2018 - 3:15pm
Event ends: 
02/18/2018 - 11:00am
Cost:
$0.00

Program Agenda

* Please click the program's title to view each presentation.

Friday, February 16, 2018

3:15 – 4:00 PMRegistration / break
4:00 – 4:30 PMOpening Remarks & Pre-Meeting Assessment
Objectives
  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices
4:30 – 5:30 PMThyroid Cancer Update
R. Michael Tuttle, MD 
Objectives
  1. Describe the new 8th edition AJCC staging system
  2. Describe a rational approach to selection of thyroid cancer patients for lobectomy
  3. Describe a rational approach to active surveillance in low risk thyroid cancer
5:30 – 7:30 PMCushing’s Syndrome: Diagnostic and treatment dilemmas
T. Brooks Vaughan, MD; Kristen Riley, MD, FACS 
Objectives
  1. Review the most recent information regarding the diagnosis and source localization of Cushing’s syndrome/disease
  2. Review the current state of the art in surgical and radio therapeutic options for Cushing’s disease
  3. Apply this knowledge in real-world, case-based diagnostic and treatment scenarios
7:30 – 8:30 PMWelcome Reception

Saturday, February 17, 2018

7:00 – 8:00 AMContinental Breakfast / Registration Open
8:00 – 9:00 AMObesity Management: Medical and surgical approaches
Donna H. Ryan, MD
Objectives
  1. Describe, according to AACE Guidelines, steps for assessment and staging to direct medical management of obesity
  2. Discuss the safety and efficacy of currently available medications approved for chronic weight management
  3. Describe the efficacy and safety of common bariatric surgery procedures and the long term nutritional support of patients who have these procedures
9:00 – 9:45 AMManaging Osteoporosis in 2018
Nelson Watts, MD, FACP, CCD, MACE
Objectives
  1. Understand the mechanism of action of denosumab
  2. Appreciate what happens to BMD, BTM and fracture risk when denosumab is stopped
  3. Understand new agents in development
9:45 – 10:15 AMBreak
10:15 – 11:00 AMEndocrine Hypertension
Richard Auchus, MD, PhD, FACE
Objectives
  1. Analyze aldosterone/renin ratios in the context of medication and serum potassium
  2. Interpret the results of adrenal vein sampling
  3. List the medications that interfere with the evaluation of pheochromocytoma
11:00 – 12:00 PMPCSK9 Inhibitors and Diabetes
Chip Lavie, MD, FACC, FACP, FCCP, FESPM
Objectives
  1. Review the importance of lipids in preventive cardiology
  2. Review the effects of statins but also limitations
  3. Describe what PCSK9's are
12:00 - 12:15 PMPost Assessment
12:15 - 1:15 PMLunch
1:15 – 1:45 PMPre-Meeting Assessment
Objectives
  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices
1:45 – 2:45 PMEndocrine Coding 101
Vanessa Lankford, CPC, CMOM, CMCO, AACE-CEC 
Objectives
  1. Review correct billing and coding guidelines relating to endocrinology services
  2. Define areas of opportunities to improve documentation
  3. Describe resources that can be utilized to ensure appropriate coding and billing relating to endocrinology
2:45 – 3:30 PMPractical Strategies for Management of the Pseudo-Endocrine Patient
Michael McDermott, MD 
Objectives
  1. Describe symptoms and signs commonly presented by the pseudo-endocrine patient
  2. Review diagnostic evaluations appropriate for the pseudo-endocrine patient
  3. Discuss management strategies for the pseudo-endocrine patient
7:00 PMFamily Dinner at Galatoire’s

Sunday, February 18. 2018

7:10 – 7:30 AMCoffee Break
7:30 – 8:30 AMHeart Failure – The Frequent Forgotten and Often Fatal Complications of Diabetes
David S.H. Bell, MB, FACP, FACE
Objectives
  1. Describe the causes of the high incidence of heart failure in the diabetes population
  2. Identify the oral hypoglycemic agents that increase and decrease the incidence of heart failure on the diabetes patient
  3. Recognize the need to screen for heart failure in the diabetes patient
8:30 – 9:30 AMDiabetes: A cardiac condition manifesting as hyperglycemia
David S.H. Bell, MB, FACP, FACE
Objectives
  1. Identify ideologies for increased incidence of cardiovascular disease in the type diabetes patient
  2. Recognize the role of postprandial hyperglycemia and hypoglycemia
  3. Recognize results of GLP-1 receptor agonists in cardiovascular outcomes trails
9:30 – 9:45 AMPost Assessment
Objectives
  1. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities
9:45 – 11:00 AMFamily Brunch / Chapter Business Meeting
11:00 AMAdjourn
Renaissance New Orleans Arts Warehouse District Hotel
700 Tchoupitoulas St
New Orleans, LA 70130
United States
+1 (504) 613-2330

Richard Auchus, MD, PhD, FACE
Professor of Internal Medicine/Endocrinology and Pharmacology
Endocrinology Fellowship Program Director
University of Michigan
Ann Arbor, MI

David S.H. Bell, MB, FACP, FACE
Professor of Medicine (Retired)
University of Alabama
Irondale, AL

Vanessa Lankford, CPC, CMCO, CMOM, AACE-CEC
Practice Management Coordinator
American Association of Clinical Endocrinologists
Jacksonville, FL

Carl "Chip" Lavie, MD, FACC, FACP, FCCP
Medical Director, Cardiac Rehabilitation and Prevention
Director, Stress Testing Laboratory
Ochsner Health System, Cardiology Department
New Orleans, LA

Michael McDermott, MD
Professor of Medicine and Clinical Pharmacy
University of Colorado Denver School of Medicine
Director, Endocrinology and Diabetes Practice
University of Colorado Hospital
Denver, CO

Kristen Riley, MD, FACS
Associate Professor, Department of Neurosurgery
Director, Neurosurgical Pituitary Disorders Clinic
University of Alabama at Birmingham
Birmingham, AL

Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA

R. Michael Tuttle, MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

T. Brooks Vaughan, MD
Associate Professor of Medicine and Neurosurgery
University of Alabama at Birmingham
Birmingham, AL

Nelson B. Watts, MD, FACP, CCD, MACE
Director
Mercy Health Osteoporosis and Bone Health Services
Cincinnati, OH

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the Southern States Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 11.75 AMA
  • 11.75 Attendance

Accreditation Period

Course opens: 
02/16/2018
Course expires: 
02/17/2019

Price

Cost:
$0.00
Please login or register to take this course.